Investors with a lot of money to spend have taken a bearish stance on Amgen AMGN.
And retail traders should know.
We noticed this today when the positions showed up on publicly available options history that we track here at Benzinga.
Whether these are institutions or just wealthy individuals, we don't know. But when something this big happens with AMGN, it often means somebody knows something is about to happen.
Today, Benzinga's options scanner spotted 11 options trades for Amgen.
This isn't normal.
The overall sentiment of these big-money traders is split between 27% bullish and 63%, bearish.
Out of all of the options we uncovered, there was 1 put, for a total amount of $306,375, and 10, calls, for a total amount of $382,064.
Predicted Price Range
Analyzing the Volume and Open Interest in these contracts, it seems that the big players have been eyeing a price window from $220.0 to $300.0 for Amgen during the past quarter.
Insights into Volume & Open Interest
In terms of liquidity and interest, the mean open interest for Amgen options trades today is 1857.57 with a total volume of 1,376.00.
In the following chart, we are able to follow the development of volume and open interest of call and put options for Amgen's big money trades within a strike price range of $220.0 to $300.0 over the last 30 days.
Amgen Option Volume And Open Interest Over Last 30 Days
Significant Options Trades Detected:
| Symbol | PUT/CALL | Trade Type | Sentiment | Exp. Date | Ask | Bid | Price | Strike Price | Total Trade Price | Open Interest | Volume |
|---|---|---|---|---|---|---|---|---|---|---|---|
| AMGN | PUT | SWEEP | BEARISH | 05/16/25 | $14.25 | $14.2 | $14.25 | $260.00 | $306.3K | 231 | 109 |
| AMGN | CALL | SWEEP | BULLISH | 01/17/25 | $46.0 | $44.15 | $46.0 | $220.00 | $73.6K | 239 | 9 |
| AMGN | CALL | SWEEP | BULLISH | 09/19/25 | $14.7 | $14.35 | $14.7 | $290.00 | $63.2K | 60 | 43 |
| AMGN | CALL | TRADE | BULLISH | 04/17/25 | $3.3 | $3.15 | $3.3 | $300.00 | $40.9K | 493 | 129 |
| AMGN | CALL | TRADE | BEARISH | 06/20/25 | $10.25 | $9.85 | $9.85 | $290.00 | $35.4K | 158 | 94 |
About Amgen
Amgen is a leader in biotechnology-based human therapeutics. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). The 2023 Horizon acquisition brings several rare-disease drugs, including thyroid eye disease drug Tepezza. Amgen also has a growing biosimilar portfolio.
Having examined the options trading patterns of Amgen, our attention now turns directly to the company. This shift allows us to delve into its present market position and performance
Current Position of Amgen
- With a trading volume of 1,552,050, the price of AMGN is down by -0.1%, reaching $261.96.
- Current RSI values indicate that the stock is may be approaching overbought.
- Next earnings report is scheduled for 22 days from now.
What Analysts Are Saying About Amgen
Over the past month, 3 industry analysts have shared their insights on this stock, proposing an average target price of $296.0.
Turn $1000 into $1270 in just 20 days?
20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. Click here for access. * Maintaining their stance, an analyst from Wells Fargo continues to hold a Equal-Weight rating for Amgen, targeting a price of $280. * Consistent in their evaluation, an analyst from Truist Securities keeps a Hold rating on Amgen with a target price of $298. * An analyst from Piper Sandler persists with their Overweight rating on Amgen, maintaining a target price of $310.
Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for Amgen with Benzinga Pro for real-time alerts.
© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
